Haniva was awarded a US Patent In March, 2017 for the Combination Therapy of non-thermal plasma and any DNA damaging agent activated by hypoxia (Patent number 9,586,056). As of May, 2021, they also received patent approval for their combination therapy from the Australian government. 

Biotechnology

Haniva Technology

Shoshanna Zucker

Doug Dufaux

The leadership team of Hanova Technology has a wealth of experience in the engineering and commercialization industries. They have worked as consultants and directors at various companies, and have also founded their own successful organization. They hold degrees from Washington University in St. Louis and other prestigious institutions. This team is well-equipped to lead Hanova Technology to success.

Leadership Team

About

Team members